Eris Lifesciences files SEBI Depository Certificate for Q4FY26
Eris Lifesciences Limited submitted a confirmation certificate for Q4FY26 under SEBI regulations. The company's RTA, MUFG Intime India, confirmed processing of dematerialized securities and updates to the register of members within prescribed timelines.
This is a standard compliance filing required by SEBI and does not involve any new strategic decisions, financial performance updates, or significant corporate actions that would impact the company's valuation or operations.
The announcement is a routine regulatory filing and does not contain any information that would positively or negatively impact the company's stock or operations.
Eris Lifesciences Limited has submitted a Confirmation Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026. This certificate was received from their Registrar and Share Transfer Agent (RTA), MUFG Intime India Private Limited (formerly Link Intime India Private Limited).
The RTA confirmed that securities received from depository participants for dematerialization during the quarter were processed, accepted or rejected, and subsequently listed on the stock exchanges. They also confirmed that the security certificates received for dematerialization were duly verified, mutilated, cancelled, and the depositories were substituted as registered owners within the prescribed timelines.
The company has duly confirmed and certified the information provided by the RTA. This submission is for the information and records of the stock exchanges and depositories.
What to do with a filing like this
Eris Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Eris Lifesciences Limited. Read the original for the full detail.